LHLiangbiaoGeorge Hu

LiangbiaoGeorge Hu

*This is an algorithmically generated author record based on publicly available information.

LiangbiaoGeorge Hu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Jason D Blom

    Pfizer Global Research & Development, St. Louis Laboratories, Pfizer Inc, St. Louis, MO, 63017, USA

    1 shared publication
  • Jon G Selbo

    Pfizer Global Research & Development, St. Louis Laboratories, Pfizer Inc, St. Louis, MO, 63017, USA

    1 shared publication
  • Kimberly Shevlin

    Pfizer Global Research & Development, St. Louis Laboratories, Pfizer Inc, St. Louis, MO, 63017, USA

    1 shared publication
  • Na Li

    Pfizer Global Research & Development, St. Louis Laboratories, Pfizer Inc, St. Louis, MO, 63017, USA

    1 shared publication
  • Po-Chang Chiang

    Department of Pharmaceutical Science, Pfizer Global Research and Development, St. Louis Laboratories, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, USA

    1 shared publication
  • Timothy G Brayman

    Pfizer Global Research & Development, St. Louis Laboratories, Pfizer Inc, St. Louis, MO, 63017, USA

    1 shared publication

Latest Publications

  • Open Access

    Comparison of In vitro Nanoparticles Uptake in Various Cell Lines and In vivo Pulmonary Cellular Transport in Intratracheally Dosed Rat Model

    by Yurong Lai, Po-Chang Chiang, Jason D Blom, Na Li, Kimberly Shevlin, Timothy G Brayman, Yiding Hu, Jon G Selbo, LiangbiaoGeorge Hu

    In present study, the potential drug delivery of nanoformulations was validated via the comparison of cellular uptake of nanoparticles in various cell lines and in vivo pulmonary cellular uptake in intratracheally (IT) dosed rat model. Nanoparticles were prepared by a bench scale wet milling device and incubated with a series of cell lines, including Caco-2, RAW, MDCK and MDCK transfected MDR1 cells. IT dosed rats were examined for the pulmonary cellular uptake of nanoparticles. The processes of nanoparticle preparation did not alter the crystalline state of the material. The uptake of nanoparticles was observed most extensively in RAW cells and the least in Caco-2 cells. Efflux transporter P-gp did not prevent cell from nanoparticles uptake. The cellular uptake of nanoparticles was also confirmed in bronchoalveolar lavage (BAL) fluid cells and in bronchiolar epithelial cells, type II alveolar epithelial cells in the intratracheally administrated rats. The nanoparticles uptake in MDCK, RAW cells and in vivo lung epithelial cells indicated the potential applications of nanoformulation for poorly soluble compounds. The observed limited direct uptake of nanoparticles in Caco-2 cells suggests that the improvement in oral bioavailability by particle size reduction is via increased dissolution rate rather than direct uptake.